ARDS, HumanNorthCARDSNCT04729075
Associations Between COVID-19 ARDS Treatment, Clinical Trajectories and Liberation From Mechanical Ventilator - an Analysis of the NorthCARDS Dataset
An observational study of ARDS, Human and Covid19, run by Northwell Health at 1 site in United States.
Trial summary
The mortality rates associated with COVID-19 related ARDS (COVIDARDS) have varied from observational reports from around the world. This has ranged from 44% (28 day mortality) in the UK to 36% (28 day mortality from ICU admission) in Italian studies, to 32% (all-cause 28 day mortality) in Spain. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- ARDS, Human, Covid19
- What is being tested?
- ARDS and COVID19 treatments
- How many people
- 1,800 participants
- Where
- 1 siteUnited States
- Study dates
- 19 Jan 2021to 19 Jan 2021
- How long will I take part?
- 6 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: COVID-19 ARDS patients receiving mechanical ventilation
Who may be able to join
- Inpatients at any of the hospitals within the Northwell Health system
- COVID19 PCR positive
- meeting ARDS criteria (defined as)
- PaO2:FiO2 <300 for at least 2 consecutive values (including 2 S/F values)
- bilateral infiltrates
- mechanical ventilation (NIMV or IMV with PEEP 5)
- Timeframe March 1, 2020 until December 30, 2020
Who cannot join
- Patients admitted for surgical procedures
- infiltrates described as being due to cardiogenic pulmonary edema without COVID-19 pneumonia
- improvement of paO2:FiO2 to > 300 within 48 hours
Trial locations and contacts
1 site in 1 country.
United States1 site
Feinstein Institutes for Medical Research
Manhasset, New York, 11030
About this study
Official title: Towards Precision Medicine for COVID-19 ARDS - An Analysis of the NorthCARDS (Northwell Health COVID-19 ARDS) Dataset to Identify Associations Between Patient-level Factors, Inpatient Treatment and Clinical Trajectories on Mechanical Ventilation Liberation and Survival
The mortality rates associated with COVID-19 related ARDS (COVIDARDS) have varied from observational reports from around the world. This has ranged from 44% (28 day mortality) in the UK to 36% (28 day mortality from ICU admission) in Italian studies, to 32% (all-cause 28 day mortality) in Spain. Predictive models have identified risk factors for COVID-19 hospitalized patients' mortality to include male sex, obesity, age, obesity, comorbidities including chronic lung disease and hypertension, as well as biomarkers including high levels of D-Dimer, LDH and CRP. In addition, practice patterns, such as drugs that were administered, timing of mechanical ventilation and adherence to established lung protective ventilation protocols are known to be variable across sites and have changed over time.
The investigators propose to analyze outcomes for patients with COVIDARDS within the NorthCARDS dataset (a dataset of over 1500 patients with COVID-19 related ARDS across the Northwell Health System in the NYC metropolitan region and Long Island, NY) to understand differences in hospital survival and in the time to liberation from mechanical ventilation, specifically looking at the associations between baseline patient factors, changes in biomarkers, respiratory function and hemodynamics over time, and treatments administered. The analyses will be based on three hypotheses:
Read more
H.1. Worsening trajectories of: oxygenation index (OI), respiratory system compliance (C), and inflammatory markers will be associated with lower hospital survival.
H.2. Higher duration of deep sedation and paralytics will be associated with greater time to liberation from mechanical ventilation. This risk will be increased in patients with worsening trajectories of OI, C, and inflammatory markers over time.
H.3. Type of mechanical ventilator, specifically the time on portable mechanical ventilator, is associated with hospital mortality and with inability to liberate from mechanical ventilator despite controlling for risk factors of changes in OI, C and Inflammatory markers over time, and the use of paralytics and deep sedation.
Read the detailed description
The investigators will leverage the NorthCARDS dataset for this analysis. This dataset includes over 1500 persons admitted to the Northwell Health System who had PCR positive COVID19 testing and were invasively mechanically ventilated for ARDS. Registry development was initiated in April 2020 and continues with prospective data collection for all mechanically ventilated COVID19 ARDS patients among the Northwell Health hospitals. Data structuring and engineering is informed by weekly multi-disciplinary review including frontline clinicians, data scientists, biostatisticians and data engineers within medical informatics. Random selection of patients for individual 'manual' chart review occurs for data assumptions and recording.
The two outcomes to be modeled using multivariable regression analyses will be:
- Index hospital survival and
- Time to liberation from mechanical ventilation.
Liberation from mechanical ventilation will be defined as non-palliative extubation and persistent extubation for greater than one week. Outcomes will be obtained from electronic health record queries. Patients in whom the investigators do not have outcomes data by November 30,2020 will be censored in analyses, and descriptive statistics will be summarized and presented separately.
The investigators will approach this analysis using both hypothesis-driven methods wherein known risk factors for poor outcomes will be included in the multivariable regression models (logistic regression for Model 1, and Cox Proportional Hazards for Model 2); and investigators will also perform data-driven variable selection for the models. A priori defined risk factors that will be included in the models will be: Age, Gender, BMI, functional status at baseline (nursing home versus community admission), Comorbidities (coronary artery disease, Chronic Kidney Disease, Neurologic disorders, COPD, Diabetes, Active cancer, Hypertension); Inpatient treatments (for continuous values will be (max, median, trajectory)) including PEEP levels, Driving Pressure, FiO2, hypoxemia (Pao2:Fio2), type of mechanical ventilator (portable versus not), COVID-targeted medications (e.g., azithromycin, hydroxychloroquine, corticosteroids); and end-organ damage in-hospital: liver dysfunction, Kidney dysfunction, coagulopathy, (captured via SOFA scores), cardiac dysfunction, and shock requiring vasopressor/inotrope. Calendar-time, hospital type (community versus tertiary hospital) and hospital capacity (measured as number of hospital beds filled and time from admission order in ER to being transferred to an inpatient bed) will also be included in the analyses to account for temporal and systemic influences of outcomes.
The final models will include variables selected through a backward selection process, together with variables ranked highly through data-driven methods including a logistic regression model regularized by Lasso penalty and Cox Proportional Hazards Model regularized by Lasso penalty. Model performance will be assessed for Model 1 (hospital survival) using the C-statistic.
Model performance for Model 2 (time to mechanical ventilator liberation) will be based on the C-statistic adapted for censored data.
Missing Data management: When the outcome data is missing for Model (1) (hospital survival), if there is less than 5% of outcomes missing, complete case analysis will be used; if there is more than 5% missing, sensitivity analysis will be performed by assuming all the missing outcomes to be either expired or alive to see if the results are similar to those using complete case analysis.
When the outcome data is missing for Model (2) (liberation from mechanical ventilation) the missing outcome will be considered as censored.
If overall < 5% of our cohort has missing data for any risk factors, only patients with complete values for all risk factors will be included (others will be discarded).
If > 5% of the cohort is missing data for any risk factor, the missing data will be imputed using multiple imputation.
If a risk factor is missing in > 50% of patients the variable will not be included in the analysis.
Feature Engineering/Data Reduction: We will also test whether combinations of covariables considered as one covariable increases model performance. This will include COVID-19 illness index (combination of hyperinflammatory markers, PaO2:FiO2 index at the time of intubation, requiring vasopressors at the time of intubation, and Oxygenation Index) and adherence to standard ARDS treatment protocols (Driving Pressure, whether receiving less than 6-8 cc/kg predicted body weight and whether or not proned).
- Conditions
- ARDS, Human, Covid19
- Being tested
- ARDS and COVID19 treatments
- Medical subject headings
- Respiratory Distress Syndrome, COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ARDS and COVID19 treatmentsOther
Interventions that will be analyzed will include: immunomodulation; oxygen supplementation type, duration and level; mechanical ventilation type, duration; diuresis; inotrope/vasopressors; prone positioning
What is being measured
The primary outcome is the main question the study is designed to answer.
Index Hospital Survival
Through duration of hospital stay for up to 1 year
Measured: up to 1 year
Time to Mechanical Ventilator Liberation
Censored at 6-months of follow-up; Liberation from mechanical ventilation will be defined as non-palliative extubation and persistent extubation for greater than one week.
Measured: 6 months
Secondary outcomes (1)
Hospital Readmission
Within 6 months of follow up after index hospitalization
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jan 2021
- Study start19 Jan 2021
- Primary completion19 Jan 2021
- Study completion19 Jan 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for ARDS, HumanStudies of the same condition, open and under way.
- More trials run by Northwell HealthThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 1,800 participants (actual)
- Target duration
- 6 Months
Sponsor and investigators
- Lead sponsor
- Northwell Health
- Sponsor type
- University, hospital or other
- Collaborators
- BioSymetrics, Feinstein Institute for Medical Research
- Responsible party
- Sponsor
- Investigators
- Negin Hajizadeh, MD, MPH, Principal investigator, Northwell Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04729075
- Sponsor's protocol ID
- 19-0598
- Acronym
- NorthCARDS
- Status last verified
- Mar 2023
- First submitted
- 19 Jan 2021
- Last updated
- 4 Apr 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Access to the NorthCARDS Registry is planned via DUA
Publications
Cheyne H, Gandomi A, Hosseini Vajargah S, Catterson VM, Mackoy T, McCullagh L, Musso G, Hajizadeh N. Drivers of mortality in COVID ARDS depend on patient sub-type. Comput Biol Med. 2023 Nov;166:107483. doi: 10.1016/j.compbiomed.2023.107483. Epub 2023 Sep 16.
PubMed 37748219
Study at a glance
From the registry record, last updated by the sponsor on 4 Apr 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Towards Precision Medicine for COVID-19 ARDS - An Analysis of the NorthCARDS (Northwell Health COVID-19 ARDS) Dataset to Identify Associations Between Patient-level Factors, Inpatient Treatment and Clinical Trajectories on Mechanical Ventilation Liberation and Survival
- ClinicalTrials.gov ID
- NCT04729075
- Acronym / sponsor ID
- NorthCARDS / 19-0598
- Conditions
- ARDS, Human, Covid19
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,800 participants (actual)
- Lead sponsor
- Northwell HealthUniversity, hospital or other
- Collaborators
- BioSymetrics, Feinstein Institute for Medical Research
- Study start
- 19 Jan 2021 (actual)
- Primary completion
- 19 Jan 2021 (actual)
- Study completion
- 19 Jan 2021 (actual)
- First posted
- 28 Jan 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The mortality rates associated with COVID-19 related ARDS (COVIDARDS) have varied from observational reports from around the world. This has ranged from 44% (28 day mortality) in the UK to 36% (28 day mortality from ICU admission) in Italian studies, to 32% (all-cause 28 day mortality) in Spain. Predictive models have identified risk factors for COVID-19 hospitalized patients' mortality to include male sex, obesity, age, obesity, comorbidities including chronic lung disease and hypertension, as well as biomarkers including high levels of D-Dimer, LDH and CRP. In addition, practice patterns, such as drugs that were administered, timing of mechanical ventilation and adherence to established lung protective ventilation protocols are known to be variable across sites and have changed over time.
The investigators propose to analyze outcomes for patients with COVIDARDS within the NorthCARDS dataset (a dataset of over 1500 patients with COVID-19 related ARDS across the Northwell Health System in the NYC metropolitan region and Long Island, NY) to understand differences in hospital survival and in the time to liberation from mechanical ventilation, specifically looking at the associations between baseline patient factors, changes in biomarkers, respiratory function and hemodynamics over time, and treatments administered. The analyses will be based on three hypotheses:
H.1. Worsening trajectories of: oxygenation index (OI), respiratory system compliance (C), and inflammatory markers will be associated with lower hospital survival.
H.2. Higher duration of deep sedation and paralytics will be associated with greater time to liberation from mechanical ventilation. This risk will be increased in patients with worsening trajectories of OI, C, and inflammatory markers over time.
H.3. Type of mechanical ventilator, specifically the time on portable mechanical ventilator, is associated with hospital mortality and with inability to liberate from mechanical ventilator despite controlling for risk factors of changes in OI, C and Inflammatory markers over time, and the use of paralytics and deep sedation.
Detailed description
The investigators will leverage the NorthCARDS dataset for this analysis. This dataset includes over 1500 persons admitted to the Northwell Health System who had PCR positive COVID19 testing and were invasively mechanically ventilated for ARDS. Registry development was initiated in April 2020 and continues with prospective data collection for all mechanically ventilated COVID19 ARDS patients among the Northwell Health hospitals. Data structuring and engineering is informed by weekly multi-disciplinary review including frontline clinicians, data scientists, biostatisticians and data engineers within medical informatics. Random selection of patients for individual 'manual' chart review occurs for data assumptions and recording.
The two outcomes to be modeled using multivariable regression analyses will be:
- Index hospital survival and
- Time to liberation from mechanical ventilation.
Liberation from mechanical ventilation will be defined as non-palliative extubation and persistent extubation for greater than one week. Outcomes will be obtained from electronic health record queries. Patients in whom the investigators do not have outcomes data by November 30,2020 will be censored in analyses, and descriptive statistics will be summarized and presented separately.
The investigators will approach this analysis using both hypothesis-driven methods wherein known risk factors for poor outcomes will be included in the multivariable regression models (logistic regression for Model 1, and Cox Proportional Hazards for Model 2); and investigators will also perform data-driven variable selection for the models. A priori defined risk factors that will be included in the models will be: Age, Gender, BMI, functional status at baseline (nursing home versus community admission), Comorbidities (coronary artery disease, Chronic Kidney Disease, Neurologic disorders, COPD, Diabetes, Active cancer, Hypertension); Inpatient treatments (for continuous values will be (max, median, trajectory)) including PEEP levels, Driving Pressure, FiO2, hypoxemia (Pao2:Fio2), type of mechanical ventilator (portable versus not), COVID-targeted medications (e.g., azithromycin, hydroxychloroquine, corticosteroids); and end-organ damage in-hospital: liver dysfunction, Kidney dysfunction, coagulopathy, (captured via SOFA scores), cardiac dysfunction, and shock requiring vasopressor/inotrope. Calendar-time, hospital type (community versus tertiary hospital) and hospital capacity (measured as number of hospital beds filled and time from admission order in ER to being transferred to an inpatient bed) will also be included in the analyses to account for temporal and systemic influences of outcomes.
The final models will include variables selected through a backward selection process, together with variables ranked highly through data-driven methods including a logistic regression model regularized by Lasso penalty and Cox Proportional Hazards Model regularized by Lasso penalty. Model performance will be assessed for Model 1 (hospital survival) using the C-statistic.
Model performance for Model 2 (time to mechanical ventilator liberation) will be based on the C-statistic adapted for censored data.
Missing Data management: When the outcome data is missing for Model (1) (hospital survival), if there is less than 5% of outcomes missing, complete case analysis will be used; if there is more than 5% missing, sensitivity analysis will be performed by assuming all the missing outcomes to be either expired or alive to see if the results are similar to those using complete case analysis.
When the outcome data is missing for Model (2) (liberation from mechanical ventilation) the missing outcome will be considered as censored.
If overall < 5% of our cohort has missing data for any risk factors, only patients with complete values for all risk factors will be included (others will be discarded).
If > 5% of the cohort is missing data for any risk factor, the missing data will be imputed using multiple imputation.
If a risk factor is missing in > 50% of patients the variable will not be included in the analysis.
Feature Engineering/Data Reduction: We will also test whether combinations of covariables considered as one covariable increases model performance. This will include COVID-19 illness index (combination of hyperinflammatory markers, PaO2:FiO2 index at the time of intubation, requiring vasopressors at the time of intubation, and Oxygenation Index) and adherence to standard ARDS treatment protocols (Driving Pressure, whether receiving less than 6-8 cc/kg predicted body weight and whether or not proned).
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 6 Months
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- COVID-19 ARDS patients receiving mechanical ventilation
Key inclusion criteria (7 listed)
- Inpatients at any of the hospitals within the Northwell Health system
- COVID19 PCR positive
- meeting ARDS criteria (defined as)
- Timeframe March 1, 2020 until December 30, 2020
Key exclusion criteria (3 listed)
- Patients admitted for surgical procedures
- infiltrates described as being due to cardiogenic pulmonary edema without COVID-19 pneumonia
- improvement of paO2:FiO2 to > 300 within 48 hours
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ARDS and COVID19 treatmentsInterventions that will be analyzed will include: immunomodulation; oxygen supplementation type, duration and level; mechanical ventilation type, duration; diuresis; inotrope/vasopressors; prone positioning | Other | – |
Primary outcome
Index Hospital Survival
Time frame: up to 1 year
Through duration of hospital stay for up to 1 year
Time to Mechanical Ventilator Liberation
Time frame: 6 months
Censored at 6-months of follow-up; Liberation from mechanical ventilation will be defined as non-palliative extubation and persistent extubation for greater than one week.
1 secondary outcome
Hospital Readmission
Time frame: 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Apr 2023.
- Derived from this study: PubMed 37748219Cheyne H, Gandomi A, Hosseini Vajargah S, Catterson VM, Mackoy T, McCullagh L, Musso G, Hajizadeh N. Drivers of mortality in COVID ARDS depend on patient sub-type. Comput Biol Med. 2023 Nov;166:107483. doi: 10.1016/j.compbiomed.2023.107483. Epub 2023 Sep 16.
- Individual participant dataSharing planned: Undecided. Access to the NorthCARDS Registry is planned via DUA
Related trials for ARDS, Human
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Not yet recruitingObservational study
Development and Multicenter Validation of an Explainable System for Neonatal ARDS-Compatible Phenotyping
Acute Respiratory Distress Syndrome
RecruitingObservational study
Assessment of Blood Viscosity in ARDS (Acute Respiratory Distress Syndrome)
ARDS
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
RecruitingObservational study
Effect of Transpulmonary MP on Prognosis of Patients With Severe ARDS Treated With VV-ECMO
Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Negin Hajizadeh, MD, MPH principal investigator
Northwell Health
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of ARDS, Human and Covid19, run by Northwell Health at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Index Hospital Survival (time frame: up to 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04729075, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Apr 2023.